Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

daratumumab

View Patient Information
A human immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, with immunomodulating and antineoplastic activities. Upon administration, daratumumab targets and binds to CD38 expressed on tumor cells. This triggers direct cell killing, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity (CDC) in CD38-expressing tumor cells. In addition, binding to CD38 by daratumumab depletes CD38-expressing immunosuppressive regulatory T and B cells and myeloid-derived suppressor cells (MDSCs). CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD38 monoclonal antibody
daratumumab biosimilar HLX15
US brand name:Darzalex
Code name:HLX15
JNJ-54767414
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search